Zobrazeno 1 - 10
of 52
pro vyhledávání: '"ficlatuzumab"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Paige M. Brodrick, Edward B. Garon
Publikováno v:
Drugs. 81:547-554
The tyrosine kinase receptor mesenchymal epithelial transition (MET) is a proto-oncogene that, through the activation of the MET-hepatocyte growth factor (HGF) pathway, encodes a variety of biological processes, including cell development, proliferat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::322b9846006777f037261e4a1111681c
https://doi.org/10.1007/s40265-021-01477-2
https://doi.org/10.1007/s40265-021-01477-2
Autor:
Karin M.L. Gaensler, Charalambos Andreadis, Ravi K. Patel, Michael Flanders, Chun Jimmie Ye, Arjun A. Rao, Rebecca L. Olin, Vivian Weinberg, Bradley W. Blaser, Tommy Jiang, Frank McCormick, David P. Carbone, Pamela N. Munster, Aaron C Logan, Victoria E. Wang, Gregory K. Behbehani, Lloyd E. Damon, Blythe Durbin-Johnson, Matthew L. Settles, Peter H. Sayre, Gabriel N. Mannis, Thomas G. Martin, Gabriela K. Fragiadakis, Emma McMahon
Publikováno v:
Blood Cancer Discov
Blood cancer discovery, vol 2, iss 5
Blood cancer discovery, vol 2, iss 5
Acute myeloid leukemia (AML) patients refractory to induction therapy or relapsed within 1 year have poor outcomes. Autocrine production of hepatocyte growth factor by myeloid blasts drives leukemogenesis in preclinical models. A phase Ib trial evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af9f5ea3caf0d25186aa2f35c09bf3b
https://pubmed.ncbi.nlm.nih.gov/34514432
https://pubmed.ncbi.nlm.nih.gov/34514432
Autor:
James Ohr, Seungwon Kim, Laura P. Stabile, Julie E. Bauman, William E. Gooding, Robert L. Ferris, Jonas T. Johnson, Umamaheswar Duvvuri, John Winslow, Gerald J. Wallweber, Autumn Gaither-Davis, Adam C. Soloff, Jennifer R. Grandis
Publikováno v:
Cancers, Vol 12, Iss 1537, p 1537 (2020)
Cancers
Cancers, vol 12, iss 6
Volume 12
Issue 6
Cancers
Cancers, vol 12, iss 6
Volume 12
Issue 6
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor-intrinsic resistance mechanism is cross-talk between the EGFR and hepatocyte growt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89ae73f09d9f6445152f5e6f9200dc8
https://www.mdpi.com/2072-6694/12/6/1537
https://www.mdpi.com/2072-6694/12/6/1537
Autor:
Amy Gallagher
Publikováno v:
Oncology Times. 43:1-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d25ef4815b528b08247c6ead6479ff68
https://doi.org/10.1097/01.cot.0000789312.35754.d9
https://doi.org/10.1097/01.cot.0000789312.35754.d9
Autor:
Amirhossein Sahebkar, Behzad Behnam, Hossein M. Orafai, Amir Hossein Mohammadzadeh, Tannaz Jamialahmadi, Yunes Panahi
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9783030550349
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9e6b17fff7777da41e98af42b6798a3
https://doi.org/10.1007/978-3-030-55035-6_3
https://doi.org/10.1007/978-3-030-55035-6_3
Autor:
Audrey Baker, Sara M. Centuori, Jessica Bauman, Christine H. Chung, Conor E. Steuer, Anshu Giri, John M. Kaczmar, Julie E. Bauman, Jameel Muzaffar, Denise J. Roe, Stefanie Obara, Kathylynn Saboda, Shethal Bearelly, Carlos Caulin, Ricklie Ann Julian, Aarti K. Bhatia, Nabil F. Saba, Barbara Burtness, Steven J. Wang
Publikováno v:
Journal of Clinical Oncology. 39:6015-6015
6015 Background: Cetuximab (C), an anti-EGFR monoclonal antibody (mAb), is approved for advanced HNSCC but benefits a minority. Crosstalk between the EGFR and hepatocyte growth factor (HGF)/cMet pathways is a known resistance mechanism. HGF is also i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66293113ce23a59326afb709cd104018
https://doi.org/10.1200/jco.2021.39.15_suppl.6015
https://doi.org/10.1200/jco.2021.39.15_suppl.6015
Autor:
Jin Seok Ahn, May Han, Wei Yin, Krista McKee, Eng Huat Tan, Shefali Agarwal, Jaroslaw Jac, Keunchil Park, Jong-Mu Sun, Quan Sing Ng, Myung-Ju Ahn, Marc Credi, Francis C. Payumo, Daniel Shao-Weng Tan, Wan-Teck Lim
Publikováno v:
Clinical Pharmacology in Drug Development
Hepatocyte growth factor (HGF)/c‐Met pathway dysregulation is a mechanism for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Ficlatuzumab (AV‐299; SCH 900105), a humanized IgG1κ HGF inhibitory monoclonal antibody, pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464c31516d4bf569e121680c36cb8207
https://pubmed.ncbi.nlm.nih.gov/29346833
https://pubmed.ncbi.nlm.nih.gov/29346833
Autor:
M M Cotreau, M Han, Ramesh K. Ramanathan, Amita Patnaik, F C Payumo, J. Jac, R Isaacs, Glen J. Weiss, Raoul Tibes, C C Hofmeister, Anthony W. Tolcher, Kyriakos P. Papadopoulos
Publikováno v:
British Journal of Cancer
Background: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1κ inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17a8a24ca6f1867c936a99f735301122
https://doi.org/10.1038/bjc.2014.290
https://doi.org/10.1038/bjc.2014.290